Pfizer Inc.'s 20-valent pneumococcal vaccine Prevnar 20 was approved by the US Food and Drug Administration on 9 June, about one month ahead of an expected new pneumococcal vaccine from Merck & Co., Inc.. It’s an important approval for Pfizer’s life cycle management strategy as it attempts to maintain sales of its top-selling Prevnar franchise in the face of new competition.
With Prevnar 20, Pfizer Aims To Maintain A Top Franchise
The successor to Pfizer’s 13-valent pneumococcal vaccine, a lynchpin of the company's lifecycle management strategy, was approved in the US.

More from New Products
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.